217 related articles for article (PubMed ID: 35006382)
1. Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy.
Dai C; Waduge P; Ji L; Huang C; He Y; Tian H; Zuniga-Sanchez E; Bhatt A; Pang IH; Su G; Webster KA; Li W
Cell Mol Life Sci; 2022 Jan; 79(1):63. PubMed ID: 35006382
[TBL] [Abstract][Full Text] [Related]
2. Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization.
Ji L; Waduge P; Hao L; Kaur A; Wan W; Wu Y; Tian H; Zhang J; Webster KA; Li W
FASEB J; 2022 Jan; 36(1):e22106. PubMed ID: 34918375
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Systemic Anti-Scg3 Therapy to Treat Oxygen-Induced Retinopathy.
Dai C; Tian H; Bhatt A; Su G; Webster KA; Li W
Front Biosci (Landmark Ed); 2022 Apr; 27(4):130. PubMed ID: 35468689
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies.
Dai C; Webster KA; Bhatt A; Tian H; Su G; Li W
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062733
[TBL] [Abstract][Full Text] [Related]
5. Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety.
Tang F; LeBlanc ME; Wang W; Liang D; Chen P; Chou TH; Tian H; Li W
Angiogenesis; 2019 Aug; 22(3):369-382. PubMed ID: 30644010
[TBL] [Abstract][Full Text] [Related]
6. Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy.
He Y; Tian H; Dai C; Wen R; Li X; Webster KA; Li W
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008775
[TBL] [Abstract][Full Text] [Related]
7. Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization.
Ji L; Waduge P; Wan W; Tian H; Li J; Zhang J; Chen R; Li W
FEBS J; 2022 Jun; 289(12):3521-3534. PubMed ID: 35038348
[TBL] [Abstract][Full Text] [Related]
8. Secretogranin III: a diabetic retinopathy-selective angiogenic factor.
Li W; Webster KA; LeBlanc ME; Tian H
Cell Mol Life Sci; 2018 Feb; 75(4):635-647. PubMed ID: 28856381
[TBL] [Abstract][Full Text] [Related]
9. Secretogranin III as a novel target for the therapy of choroidal neovascularization.
LeBlanc ME; Wang W; Ji Y; Tian H; Liu D; Zhang X; Li W
Exp Eye Res; 2019 Apr; 181():120-126. PubMed ID: 30633921
[TBL] [Abstract][Full Text] [Related]
10. Neurovascular abnormalities in retinopathy of prematurity and emerging therapies.
Dai C; Xiao J; Wang C; Li W; Su G
J Mol Med (Berl); 2022 Jun; 100(6):817-828. PubMed ID: 35394143
[TBL] [Abstract][Full Text] [Related]
11. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy.
LeBlanc ME; Wang W; Chen X; Caberoy NB; Guo F; Shen C; Ji Y; Tian H; Wang H; Chen R; Li W
J Exp Med; 2017 Apr; 214(4):1029-1047. PubMed ID: 28330905
[TBL] [Abstract][Full Text] [Related]
12. Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice.
Huang C; Ji L; Kaur A; Tian H; Waduge P; Webster KA; Li W
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509549
[TBL] [Abstract][Full Text] [Related]
13. Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy.
Ji L; Waduge P; Wu Y; Huang C; Kaur A; Oliveira P; Tian H; Zhang J; Stout JT; Weng CY; Webster KA; Li W
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445707
[TBL] [Abstract][Full Text] [Related]
14. Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1α-VEGF pathway in oxygen-induced retinopathy mice.
Xu Y; Lu X; Hu Y; Yang B; Tsui CK; Yu S; Lu L; Liang X
J Pineal Res; 2018 May; 64(4):e12473. PubMed ID: 29411894
[TBL] [Abstract][Full Text] [Related]
15. RhoB antibody alters retinal vascularization in models of murine retinopathy.
Almonte-Baldonado R; Bravo-Nuevo A; Gerald D; Benjamin LE; Prendergast GC; Laury-Kleintop LD
J Cell Biochem; 2019 Jun; 120(6):9381-9391. PubMed ID: 30536763
[TBL] [Abstract][Full Text] [Related]
16. C-CBL is required for inhibition of angiogenesis through modulating JAK2/STAT3 activity in ROP development.
Chen S; Sun Q; Sun D; Willette-Brown J; Anderson MJ; Gu Q; Lewandoski M; Hu Y; Zhu F; Wei F; Zhang J
Biomed Pharmacother; 2020 Dec; 132():110856. PubMed ID: 33125970
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signaling.
Park SW; Jun HO; Kwon E; Yun JW; Kim JH; Park YJ; Kang BC; Kim JH
Vascul Pharmacol; 2017 Mar; 90():19-26. PubMed ID: 27473515
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic effect of KH902 on retinal neovascularization.
Wang F; Bai Y; Yu W; Han N; Huang L; Zhao M; Zhou A; Zhao M; Li X
Graefes Arch Clin Exp Ophthalmol; 2013 Sep; 251(9):2131-9. PubMed ID: 23740520
[TBL] [Abstract][Full Text] [Related]
19. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.
Ristori C; Filippi L; Dal Monte M; Martini D; Cammalleri M; Fortunato P; la Marca G; Fiorini P; Bagnoli P
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):155-70. PubMed ID: 20739470
[TBL] [Abstract][Full Text] [Related]
20. Recombinant thrombomodulin domain 1 rescues pathological angiogenesis by inhibition of HIF-1α-VEGF pathway.
Huang YH; Kuo CH; Peng IC; Chang YS; Tseng SH; Conway EM; Wu HL
Cell Mol Life Sci; 2021 Dec; 78(23):7681-7692. PubMed ID: 34705054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
